Advancing Cancer Treatment Through Research & Innovation
Our research focuses on developing breakthrough treatments that combine cutting-edge science with personalized patient care, pushing the boundaries of what's possible in cancer treatment.
Current Research Projects
Our current research projects are focused on developing breakthrough treatments that combine cutting-edge science with personalized patient care, pushing the boundaries of what's possible in cancer treatment.
Efficacy of Compression Therapy for Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients with Early Breast Cancer: Insights from a Single-Centre Experience in Bangladesh
Prospective
Research Objectives:
- • Incidence of CTCAE version 5 grade 2 or higher CIPN in both upper and lower extremities during entire period of chemotherapy.
The Efficacy of Pembrolizumab for Treatment of Early Triple Negative Breast Cancer: A Single-center, Open, Randomized Controlled Trial
Primary endpoints: A) Pathological Complete Response at the time of definitive surgery B) Event-free survival in the intention-to-treat population Secondary endpoints: Overall survival at the end of 15 months
Research Objectives:
- • A prospective study to measure the efficacy of Pembrolizumab in Early Triple Negative Breast Cancer (TNBC) patients of Bangladeshi population.
Recent Publications
Peer-reviewed research contributions published in leading oncology journals, advancing the field of cancer treatment.
PATHOLOGICAL COMPLETE RESPONSE WITH PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR NEOADJUVANT TREATMENT OF EARLY TRIPLE NEGATIVE BREAST CANCER: A SINGLECENTER PROSPECTIVE STUDY FROM BANGLADESH
This observational study is aimed to find out the Pathological Complete Response (pCR) at the time of definitive surgery who had received chemotherapy along with Pembrolizumab as neoadjuvant settings. After …
Key Findings:
Results Among the 6 patients the age range is 37-75 years and only 2 was right sided where the 4 is left sided breast primary. …
THE ROLE OF CONCOMITANT MET AMPLIFICATION AND HIGH PD-L1 EXPRESSION IN NON-SMALL CELL LUNG CANCER: A CASE REPORT OF IMPLICATIONS FOR TARGETED THERAPY AND IMMUNOTHERAPY
MET amplification occurs in approximately 1-5% of treatment-naïve non-small cell lung cancer (NSCLC) cases. It can also develop as an acquired resistance mechanism, particularly after treatment with EGFR tyrosine kinase …
Key Findings:
Due to poor response with 1st line CnT, 6 cycle of 2nd line palliative ChT-IO with Atezolezumab + Pemetexed + Carboplatin + Denosumab followed by …
Characteristics of metastatic lung cancer patients on osimertinib therapy in Bangladesh
Eighty patients with metastatic lung cancer receiving osimertinib therapy were included in this descriptive cross-sectional study. This study covered patients with lung cancer metastases who were receiving osimertinib, regardless of …
Key Findings:
According to the findings, the patients' mean (±SD) age was 60.95 ±13.98 years. Patients who were between the ages of 55 and 75 had the …
Showing 1 to 3 of 19 publications
Conference Presentations & Speaking Engagements
Sharing research findings and clinical insights at leading medical conferences worldwide.
ESMO Asia 2025
Clinicopathological pathological characteristics in young breast cancer patient
A single center retrospectives study in a low and middle income country
KSMO 2025
Survival Analysis of CNS patients in Bangladesh – focusing the multidisciplinary approaches among 149 patients in a single centre retrospective analysis from 2018- 2023.
Introduction: Central Nervous Tumor (CNS) tumor is variable survival status due to its location and age groups. We tried to find selected CNS tumors among adult and child with tri-modalities treatment and compared the survival and prognostic factors among 149 patients first time in Bangladesh. Methods: Retrospective analysis was done through hospital information system among CNS tumors patient’s prescription from 2018 to 2023. Follow up was also confirmed through tele conversation where the last follow up was not recent. A model with python created to analyze the survival in different groups with log rank test and COX proportional hazard ratio also tested.
Showing 5 to 6 of 6 presentations